NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

NIDCR Science News - April 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. SARS-CoV-2 May Infect the Mouth NIDCR-led study points to role for saliva in spread of virus NIDCR • March 25, 2021 A Safe Space in the Dental Clinic Making dental visits more soothing for children with autism NIDCR • March 23, 2021 How Fungus Finds A Foothold in the Mouth Overactive ...
Source: NIDCR Science News - April 5, 2021 Category: Dentistry Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
(University of California - Los Angeles) By targeting an enzyme that plays a key role in head and neck cancer cells, UCLA researchers were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2021 Category: Cancer & Oncology Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: The first warning sign of nasopharyngeal cancer - a painless swelling
CANCER at the back of the nose, down to the throat - a type of head and neck disease - is called nasopharyngeal cancer. What are the symptoms of this deadly condition? And what are the risk factors? (Source: Daily Express - Health)
Source: Daily Express - Health - March 22, 2021 Category: Consumer Health News Source Type: news

Financial Toxicity and Survival of Patients With Cancer Financial Toxicity and Survival of Patients With Cancer
Patients with head and neck cancer who reported a high level of financial difficulty were found to have a shorter survival than patients who did not.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news

Lithium chloride promotes recovery of radiation-induced oral mucositis and dysgeusia
(International& American Associations for Dental Research) Oral mucositis and taste dysfunction (dysgeusia) occurs in nearly all patients receiving head and neck radiotherapy and tremendously affects the quality of life and treatment outcome. The study " LiCl Promotes Recovery of Radiation-Induced Oral Mucositis and Dysgeusia " published in the Journal of Dental Research (JDR), investigated the hypothesis that lithium chloride (LiCl) can promote the restoration of oral mucosa integrity and taste function after radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

'Dirty' cancer biotech startup cleans up in $525M build-to-buy deal with big pharma
Maverick's drugs — two of which enter clinical trials this year — are aimed at precisely attacking tumors in head and neck, lung, breast, prostate and other cancers while leaving nearby healthy tissue untouched. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 9, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Oral and maxillofacial reconstruction featured in Journal of the California Dental Association
 Contact: Alicia Malaby916.554.5372alicia.malaby@cda.orgSacramento, Calif. – The March 2021 issue of the Journal of the California Dental Association features the latest advances in oral and maxillofacial reconstruction. Articles discuss dental implants, modern temporomandibular joint surgery, contemporary sleep surgery and the diagnosis and treatment of oral cavity and oropharyngeal cancer.“This issue, followed by an upcoming issue on head and neck cancers, will augment health care providers’ understanding of several technical and complex areas of dentistry,” ...
Source: Dental Technology Blog - March 4, 2021 Category: Dentistry Source Type: news

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news

Division of Oncology 2 (DO2)
The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatric (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 28, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

University of Cincinnati research unveils possible new combo therapy for head and neck cancer
(University of Cincinnati) Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better. Since they're using a Food and Drug Administration-approved drug to do it, this could help people sooner than later. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2021 Category: International Medicine & Public Health Source Type: news

$3.25 million in grants to stand up to cancer will improve head and neck cancer treatments
(Stand Up To Cancer) Stand Up To Cancer ® has received $3.25 million in grants from four national nonprofits to fund research to find new treatments for head and neck cancers, which are newly diagnosed in about 65,000 Americans every year. The grants include contributions of $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance each provided $125,000. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Behaviors surrounding oral sex may increase HPV-Related cancer risk
(Johns Hopkins Medicine) A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

How Our Sex Habits May Affect Our HPV and Cancer Risk
Certain sex practices, at certain ages, increased the risk of throat cancers related to human papillomavirus. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Head and Neck Cancer Human Papillomavirus (HPV) Sexually Transmitted Diseases Throat Cancer (Journal) Source Type: news

Researchers create comprehensive database of head and neck cancers
(Johns Hopkins Medicine) Researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Head and Neck Cancer Surgery Seems Safe During COVID - 19
Links seen for severe pulmonary complications in COVID - 19 - positive patients with advanced tumor stage, critical care admission (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 29, 2020 Category: Respiratory Medicine Tags: Infections, Oncology, ENT, Pulmonology, Surgery, Critical Care, Journal, Source Type: news

Head and Neck Cancer Surgery Seems Safe During COVID-19
TUESDAY, Dec. 29, 2020 -- Head and neck cancer surgery appears to be safe during the COVID-19 pandemic, according to a study published online Dec. 21 in Cancer. Researchers from the COVIDSurg Collaborative conducted an international, observational... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST PRINCETON, N.J., Dec. 22, 2020 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... Biopharmaceuticals, Oncology Soligenix, dusquetide, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news

Study: COVID-19 rates low among those who have head, neck cancer surgery
Three percent of patients undergoing surgery for head and neck cancer in 26 countries worldwide last spring tested positive for COVID-19 within 30 days of their procedures, according to a study in the journal Cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 21, 2020 Category: Consumer Health News Source Type: news

Study reveals low risk of COVID-19 infection among patients undergoing head and neck cancer surgery
(Wiley) A recent international observational study provides important data on the safety of head and neck cancer surgery during the COVID-19 pandemic. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

NHS England Starts Pilot Trial of Blood Test for Many Cancers NHS England Starts Pilot Trial of Blood Test for Many Cancers
Patients with head and neck, pancreatic, and other hard-to-spot cancers could soon have their disease picked up early with a simple blood test if a pilot by National Health Service (NHS) England is a success.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study: Telemedicine use disparity during COVID-19 among head and neck cancer patients
(Henry Ford Health System) Retrospective research by Henry Ford otolaryngologists found telemedicine use disparity among head and neck cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2020 Category: Cancer & Oncology Source Type: news

Channeling the immune system for head and neck cancer
(University of Cincinnati) University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news

Personalized cancer vaccine clinical trial to expand following promising early results
(University of Arizona Health Sciences) A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2020 Category: International Medicine & Public Health Source Type: news

Proton Beam and Gabapentin Improve Care in Head and Neck Cancer Proton Beam and Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 6, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Proton Beam, Gabapentin Improve Care in Head and Neck Cancer Proton Beam, Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 6, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Development of a protocol for assessment of suicide risk in patients with head and neck cancer - Anderson JM, Gibbison R, Twigg JA, Kanatas A.
Head and neck cancer (HNC) is the 7th most prevalent cancer globally, with an increasing incidence in recent years which is expected to continue. For many patients, the experience of receiving a diagnosis of HNC and subsequent treatment is disturbing and t... (Source: SafetyLit)
Source: SafetyLit - November 4, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

PFUA Intake and Head and Neck and Gastric Cancer Incidence PFUA Intake and Head and Neck and Gastric Cancer Incidence
Can dietary intake of dietary long-chain n-3 polyunsaturated fatty acid protect against head and neck or upper GI cancers?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Promising breath-test for cancer
(Flinders University) The global quest to use a person's breath analysis for rapid, inexpensive and accurate early-stage testing for cancer and other diseases has taken a leap forward. In a new paper in the British Journal of Cancer, Flinders University researchers have reported significant progress in developing a method to test exhaled breath profiles which accurately differentiate head and neck cancer from non-cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2020 Category: Biology Source Type: news

Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

Decreasing treatment delays for head and neck cancer patients in South Carolina
(Medical University of South Carolina) Investigators from MUSC Hollings Cancer Center classify barriers to a recommended therapy for head and neck cancer that may mean the difference between life and death for these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

US Health Department's Caputo has cancer, spokesperson says
A spokesperson says Trump health appointee Michael Caputo has metastatic head and neck cancer (Source: ABC News: Health)
Source: ABC News: Health - September 24, 2020 Category: Consumer Health News Tags: Health Source Type: news

A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

NIDCR Science News - September 2020
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. Shining a Light on Coronavirus Antibodies Repurposed detection method gives glowing results NIDCR • August 19, 2020 Turning Back the Clock on Gum Disease Scientists reverse periodontitis in aged mice NIDCR • July 20, 2020 Scientists Chew on a New Theory of Swallowing Imaging in monkeys reveals ...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news